Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma
NCT ID: NCT03185325
Last Updated: 2021-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
62 participants
OBSERVATIONAL
2018-03-10
2019-12-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases
NCT00538551
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
NCT07065344
Study of Lymphoma in Asia
NCT01584141
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
NCT01007292
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
NCT00398177
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Micro ribosomal nucleic acids have been demonstrated to possess biomarker potentiality in multiple diseases, both individually and when combined in signature profiles. Micro ribosomal nucleic acids are short single-stranded noncoding ribosomal nucleic acids of 20-22 nucleotides that function to regulate gene expression at the posttranscriptional level. They play fundamental roles in the regulation of cellular proliferation, differentiation, and apoptosis. Dysregulation of micro ribosomal nucleic acid is a unique feature of cancers including lymphomas . Information about the functional role of micro ribosomal nucleic acid dysregulation in lymphomas is increasing day by day.
The present study focuses on the micro ribosomal nucleic acid 155 since this molecule represents a typical multifunctional micro ribosomal nucleic acid. To date, increased evidence points out that micro ribosomal nucleic acid 155 is involved in numerous biological processes including haematopoiesis, inflammation and immunity. Deregulation of micro ribosomal nucleic acid 155 has been found to be associated with different kinds of cancer, cardiovascular diseases and viral infections. Since investigation on the functional activity of micro ribosomal nucleic acid 155 started a few years ago, it is reasonable to predict that many other functions will be uncovered in the near future.
Micro ribosomal nucleic acid 155 maps within and is processed from an exon of a noncoding ribosomal nucleic acid transcribed from the B-cell Integration Cluster located on chromosome 21.
Micro ribosomal nucleic acid 155 is an oncological micro ribosomal nucleic acid with a crucial role in tumor initiation and development of several B-cell malignancies. Micro ribosomal nucleic acid 155 was upregulated in several malignancies compared to nonmalignant controls and overexpression of micro ribosomal nucleic acid 155 was further associated with poor prognosis. Elevated expression of micro ribosomal nucleic acid 155 shows potentiality as a diagnostic and prognostic biomarker in diffuse large B-cell lymphoma and chronic lymphocytic leukemia. Additionally, in vitro and in vivo studies suggest micro ribosomal nucleic acid 155 as an efficient therapeutic target, supporting its oncogenic function. The use of inhibiting anti-micro ribosomal nucleic acid structures indicates promising potential as novel anticancer therapeutics.
The search for non-invasive tools for the diagnosis and management of cancer has long been a goal of cancer research that has led to great interest in the field of circulating nucleic acids in plasma and serum.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non hodgkin lymphoma patients
bone marrow puncture and venous blood samples
bone marrow puncture and venous blood samples
bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
healthy voulnteers
venous blood samples
venous blood samples
venous blood samples are collected in healthy voulnteers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bone marrow puncture and venous blood samples
bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
venous blood samples
venous blood samples are collected in healthy voulnteers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* healthy volunteers within the same range of age.
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Merna Narouz
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Merna W Narouz
Role: PRINCIPAL_INVESTIGATOR
Assiut University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AssiutU
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma--a review. Acta Oncol. 2006;45(3):258-71. doi: 10.1080/02841860500531682.
Nogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol. 2011 May 10;29(14):1803-11. doi: 10.1200/JCO.2010.33.3252. Epub 2011 Apr 11.
Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000 Aug 1;96(3):808-22. No abstract available.
Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012 Dec;6(6):590-610. doi: 10.1016/j.molonc.2012.09.006. Epub 2012 Oct 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AssiutUniversity
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.